Bormioli Pharma
Bormioli Pharma, a leading name in the pharmaceutical packaging industry, is headquartered in Italy and operates extensively across Europe and beyond. Founded in 1927, the company has established itself as a pioneer in the design and production of glass and plastic containers, primarily serving the pharmaceutical, healthcare, and cosmetic sectors. Bormioli Pharma is renowned for its innovative solutions, including high-quality vials, bottles, and closures that ensure product safety and integrity. The company’s commitment to sustainability and advanced manufacturing processes sets it apart in a competitive market. With a strong focus on research and development, Bormioli Pharma has achieved significant milestones, solidifying its position as a trusted partner for global pharmaceutical companies.
DitchCarbon Score
How does Bormioli Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Paper Products industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bormioli Pharma's score of 22 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bormioli Pharma's reported carbon emissions
In 2023, Bormioli Pharma reported total carbon emissions of approximately 134,185,000 kg CO2e for Scope 1 and 2, alongside Scope 3 emissions of about 95,334,000 kg CO2e. This marks a slight increase in Scope 1 and 2 emissions from 2022, where they were approximately 126,655,000 kg CO2e, while Scope 3 emissions also rose from about 84,536,000 kg CO2e in the previous year. The company's emissions profile indicates a significant reliance on Scope 3 emissions, which encompass indirect emissions from the supply chain and product lifecycle. In 2022, the breakdown of Scope 3 emissions included major contributions from purchased goods and services (approximately 55,040,000 kg CO2e) and downstream transportation and distribution (about 9,828,000 kg CO2e). Despite these figures, Bormioli Pharma has not disclosed specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of documented reduction strategies suggests a need for enhanced climate commitments within the organisation. As the company continues to grow, addressing its emissions will be crucial for aligning with industry standards and global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | - | - | - |
| Scope 2 | - | - | - |
| Scope 3 | - | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bormioli Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
